Insider transaction details
Dawn Christine Maroney, president of Alignment Healthcare, Inc. (NASDAQ:ALHC), reported the sale of 29,113 shares of common stock on March 12, 2026, in a Form 4 filed with the Securities and Exchange Commission. The aggregated proceeds from the transactions totaled $507,925, with the shares sold at weighted average prices spanning $16.9919 to $17.476 per share.
The filing breaks the sale into two groups: 27,350 shares sold at a weighted-average price of $17.476, with individual transaction prices ranging from $17.035 to $18.03, and a separate block of 1,763 shares sold at a weighted-average price of $16.9919, with prices between $16.92 and $17.03. The Form 4 states these sales were executed to satisfy tax withholding obligations associated with the vesting of restricted stock units and were not discretionary trades by Maroney.
Post-transaction ownership
After these transactions, Maroney directly owns 963,702 shares of Alignment Healthcare, according to the filing.
Market context and valuation commentary
Over the prior week, ALHC shares had declined by roughly 8%, with the stock trading at approximately $17 at the time of the filing. InvestingPro analysis cited in the filing characterizes the stock as appearing undervalued at current levels, and lists Alignment Healthcare among the names on its Most Undervalued list. The company is noted in that analysis as having an implied valuation of $3.47 billion.
InvestingPro subscribers are referenced as having access to 10 additional exclusive tips for ALHC, including notes on profitability expectations, valuation metrics, and Pro Research Reports covering more than 1,400 U.S. equities.
Recent operating and analyst updates
Alignment Healthcare’s latest reported quarter showed a 25% year-over-year increase in membership for the fourth quarter, alongside a 44.4% rise in revenue that exceeded expectations. The company reported a medical benefit ratio of 87.7% and an improvement in the selling, general, and administrative expense ratio by roughly 115 basis points to 9.7%.
Following the fourth-quarter results and outlook, broker activity included Raymond James reiterating a Strong Buy rating with a $27.00 price target, and Piper Sandler maintaining an Overweight rating with a $30.00 price target. These analyst actions were cited in connection with the company’s fourth-quarter 2025 performance.
Secondary offering by General Atlantic affiliate
Separately, the filing notes a secondary offering by an affiliate of General Atlantic, L.P., consisting of 13.2 million shares of Alignment Healthcare common stock priced at $19.46 per share. The offering is expected to close in March 2026 and is structured so that Alignment Healthcare will not receive proceeds from the sale. J.P. Morgan is listed as the underwriter for that transaction.
Bottom line
The reported sales by Alignment Healthcare’s president were identified as attributable to tax-withholding requirements tied to vested restricted stock units and were not discretionary. Maroney remains a significant direct shareholder. The company’s operational results and favorable analyst commentary coexist with recent downward pressure on the stock and an active secondary offering by a major shareholder affiliate.